KRAS and cancer: Here, 0.01% of KRAS mutations could be successfully identified with picoliter-scale sample consumption, and the feasibility for genotyping low-abundance KRAS gene in 98 DNA extracted from paraffin-embedded tissues (PETs) was also explored to indicate its special usefulness in the detection of clinical samples and personalized cancer therapy.